Showing results (51-60 of 373) with videos related to
Sort By:
Pageof 38
Australian and New Zealand Journal of Public Health|April 12, 2001
Advocacy for clinical trials: do the Royal Colleges and State cancer councils play an appropriate role?P M Ellis, M H TattersallBritish Journal of Cancer|March 1, 1989
Potentiation of methotrexate lymphocytotoxicity in vitro by inhibitors of nucleoside transportJ M Hughes, M H TattersallEuropean Journal of Cancer & Clinical Oncology|March 1, 1983
Assessment of antimetabolite cytotoxicity: a comparison of clonogenic assays and tritiated deoxyuridine incorporationD J Perez, M H TattersallMolecular Pharmacology|July 1, 1982
The metabolic basis of deoxyuridine cytotoxicity. Studies of cultured human lymphoblastsD J Perez, M H TattersallEuropean Journal of Cancer & Clinical Oncology|December 1, 1982
Counting the costs of cancer therapyM L Friedlander, M H TattersallCancer Research|April 1, 1981
Methotrexate cytotoxicity in cultured human leukemic cells studied by flow cytometryI W Taylor, M H TattersallMedical and Pediatric Oncology|January 1, 1990
Diethylstilbestrol revisited in advanced breast cancer managementM J Boyer, M H TattersallBiochemical Pharmacology|July 15, 1991
Inhibition of 2-desamino-2-methyl-10-propagyl-5,8-dideazafolic acid cytotoxicity by 5,10-dideazatetrahydrofolate in L1210 cells with decrease in DNA fragmentation and deoxyadenosine triphosphate poolsJ B Kwok, M H TattersallBiochemical Pharmacology|March 15, 1995
5,10-Dideazatetrahydrofolic acid reduces toxicity and deoxyadenosine triphosphate pool, expansion in cultured L1210 cells treated with inhibitors of thymidylate synthaseL K Chong, M H TattersallCancer Genetics and Cytogenetics|August 1, 1990
Analysis of inferred cytogenetic clonal evolution in a metastatic human ovarian carcinomaC G Roberts, M H TattersallPageof 38